Akademik Veri Yönetim Sistemi
Fabad Journal of Pharmaceutical Sciences, cilt.44, sa.1, ss.47-63, 2019 (Scopus)
© 2019 Society of Pharmaceutical Sciences of Ankara (FABAD). All rights reserved.In order to cope with cancer, which is one of the most deadly diseases of our age, selectively targeted drugs against tumor cells are being developed. One of the targets in this field is EGFR. EGFR, one of the protein tyrosine kinase receptors, not only controls the biological events required for cell viability, it also helps with angiogenesis, which is essential for tumor growth and metastasis. Following the discovery of increased EGFR in tumor cells, a number of studies have been conducted to develop selective protein tyrosine kinase inhibitors against the EGFR target in tumor cells. Because of the observed resistance to the first discovered inhibitors, new EGFR tyrosine kinase inhibitors with different structural properties have been developed and divided into three groups according to their effect mode. Studies with these molecularly targeted inhibitors have concluded in exciting results and clinical development. In this study; the structure of EGFR, its effect in cancer, and EGFR tyrosine kinase inhibitors, developed up to date, have been reviewed.